{
  "id": "bayer-low-dose-aspirin",
  "recordTier": "source_traceable_archive",
  "editorial": {
    "reviewedAt": "2026-08-30",
    "status": "published_traceable_archive"
  },
  "names": {
    "brand": "BAYER LOW DOSE ASPIRIN",
    "generic": "阿司匹林",
    "aliases": [
      "Bayer Aspirin",
      "Aspirin Regimen",
      "BAYER ASPIRIN",
      "拜阿司匹灵",
      "拜阿司匹灵肠溶片",
      "aspirin",
      "acetylsalicylic acid",
      "ASA"
    ],
    "marketBrandNames": [
      {
        "name": "拜阿司匹灵®",
        "market": {
          "zh": "中国大陆（拜耳中国 2024 年有日期品牌/包装资料）",
          "en": "Mainland China (dated Bayer China 2024 brand/package material)"
        },
        "evidenceStatus": "dated_public_record",
        "note": {
          "zh": "拜耳中国资料把拜阿司匹灵®列为中国大陆 100 mg 阿司匹林肠溶片，并介绍 30 片与 90 片包装。本档案主体是美国每片 81 mg 的 BAYER LOW DOSE ASPIRIN；两个市场的强度、包装和标签不能因品牌关联或都写“低剂量/阿司匹林”而合并为同一产品。",
          "en": "Bayer China material identifies Bayer Aspirin® in Mainland China as a 100 mg enteric-coated aspirin tablet and describes 30- and 90-tablet packs. This dossier is the U.S. 81 mg-per-tablet BAYER LOW DOSE ASPIRIN product; the strengths, packages and labels in the two markets must not be merged as one product because of a related brand or shared 'low dose/aspirin' wording."
        },
        "source": {
          "id": "src_9cce1cc5fe0337c1",
          "label": "拜耳中国：拜阿司匹灵® 100 mg 阿司匹林肠溶片全新包装上市（2024）",
          "url": "https://www.bayer.com.cn/zh-hans/baiasipilingquanxinbaozhuangshangshi",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "dated_public_record",
          "documentKind": "first_party_release",
          "market": "CN",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-30",
          "reviewedAt": "2026-08-30"
        }
      }
    ],
    "mainlandChinaTradeNameCue": {
      "value": "拜阿司匹灵®",
      "status": "discovery_cue_requires_target_market_verification",
      "source": {
        "id": "src_9cce1cc5fe0337c1",
        "label": "拜耳中国：拜阿司匹灵® 100 mg 阿司匹林肠溶片全新包装上市（2024）",
        "url": "https://www.bayer.com.cn/zh-hans/baiasipilingquanxinbaozhuangshangshi",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "dated_public_record",
        "documentKind": "first_party_release",
        "market": "CN",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-30",
        "reviewedAt": "2026-08-30"
      }
    }
  },
  "identity": {
    "therapeuticArea": "疼痛与炎症",
    "sourceArchiveMarket": "美国 DailyMed 81 mg OTC 公开标签；中国大陆拜耳中国 2024 年 100 mg、30/90 片有日期品牌包装资料（不是现行批准说明书）",
    "dosageFormClass": "肠溶包衣口服片；美国资料每片 81 mg，中国大陆有日期品牌资料每片 100 mg",
    "dosageFormClassCode": "oral_modified_release",
    "route": "口服",
    "routeCode": "oral",
    "historicalApprovalEntry": "未在本页推定（应按目标市场官方记录核验）",
    "archiveSponsorText": "Bayer HealthCare LLC（美国公开标签所列）"
  },
  "matchPolicy": {
    "contract": "reviewed_name_and_exclusion_cues_v1",
    "exactMatchNames": [],
    "excludedProductCues": [],
    "exclusionPrecedence": "before_name_candidate"
  },
  "productPresentations": [
    {
      "id": "us-bayer-low-dose-aspirin-enteric-tablet-81mg-200ct-ndc-0280-2100-20",
      "marketCode": "US",
      "labelVersion": {
        "zh": "DailyMed SPL v8；标签生效 2025-12-04，发布 2025-12-05",
        "en": "DailyMed SPL v8; label effective 4 Dec 2025, published 5 Dec 2025"
      },
      "dosageForm": {
        "zh": "BAYER LOW DOSE ASPIRIN 肠溶包衣口服片",
        "en": "BAYER LOW DOSE ASPIRIN enteric-coated oral tablet"
      },
      "route": {
        "zh": "口服",
        "en": "oral"
      },
      "routeCodes": [
        "oral"
      ],
      "productCode": "NDC 0280-2100-20",
      "pouchCode": null,
      "applicationNumber": null,
      "presentationRole": null,
      "primaryStrengthBasisCode": "per_tablet",
      "primaryDisplay": {
        "zh": "每片阿司匹林 81 mg；200 片瓶装纸盒",
        "en": "Aspirin 81 mg per enteric-coated tablet; 200-tablet bottle carton"
      },
      "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=Bayer+Low+Aspirin_200ct_Ctn.jpg&setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&type=img",
      "visualStatus": "exact_public_label_package_image",
      "labeledQuantities": [
        {
          "ingredient": {
            "zh": "阿司匹林",
            "en": "aspirin"
          },
          "value": 81,
          "unit": "mg",
          "basisCode": "per_tablet",
          "basisLabel": {
            "zh": "每片标签含量；不是个人服用片数",
            "en": "labelled amount per tablet/caplet; not an individual's tablet count"
          }
        }
      ],
      "concentration": null,
      "container": {
        "typeCode": "bottle_carton",
        "typeLabel": {
          "zh": "200 片瓶装纸盒",
          "en": "200-tablet bottle carton"
        },
        "fill": null,
        "countPerPackage": 200,
        "countUnit": {
          "zh": "片/瓶装纸盒",
          "en": "tablets per bottle carton"
        }
      },
      "deliveryDevice": null,
      "compatibleReusableDevice": null,
      "listingStatus": {
        "reviewedAt": "2026-08-19",
        "currentLabelDisplayed": true,
        "ndcDirectoryListed": true,
        "marketAvailability": "not_established",
        "marketingStartDate": null,
        "marketingEndDate": null,
        "purpleBookPresentationStatus": null,
        "statusConflictRequiresManualReview": false
      },
      "package": {
        "count": 200,
        "unit": {
          "zh": "片/瓶装纸盒",
          "en": "tablets per bottle carton"
        }
      },
      "physicalClues": {
        "color": {
          "zh": "橙色与白色纸盒展示面",
          "en": "orange-and-white carton display panel"
        },
        "shape": {
          "zh": "肠溶包衣片",
          "en": "enteric-coated tablet"
        },
        "imprint": null,
        "scoreStatus": "unscored",
        "patchAreaCm2": null
      },
      "comparisonNotice": null,
      "source": {
        "id": "src_3c1cad1341a17717",
        "label": "DailyMed（NLM）：BAYER LOW DOSE ASPIRIN 当前美国 OTC 公开标签（Bayer HealthCare；SPL v8，2025-12-05 发布）",
        "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&version=8",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "publication_status_unresolved",
        "documentKind": "product_label",
        "market": "US",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-20",
        "reviewedAt": "2026-08-20"
      },
      "scope": "package_and_label_identity_only_not_personal_dosing_or_conversion"
    },
    {
      "id": "cn-bayer-aspirin-enteric-tablet-100mg-30-tablet-dated-pack-record",
      "marketCode": "CN",
      "labelVersion": {
        "zh": "拜耳中国有日期品牌包装资料，2024-11-06；不是现行批准说明书",
        "en": "Dated Bayer China brand/package material, 6 Nov 2024; not a current approved leaflet"
      },
      "dosageForm": {
        "zh": "拜阿司匹灵® 阿司匹林肠溶片",
        "en": "Bayer Aspirin® enteric-coated aspirin tablet"
      },
      "route": {
        "zh": "口服（品牌包装资料中的产品身份字段）",
        "en": "oral (product-identity field in dated brand/package material)"
      },
      "routeCodes": [
        "oral"
      ],
      "productCode": "Bayer China dated pack record: 30 tablets",
      "pouchCode": null,
      "applicationNumber": null,
      "presentationRole": null,
      "primaryStrengthBasisCode": "per_tablet",
      "primaryDisplay": {
        "zh": "每片阿司匹林 100 mg；30 片/盒（2024 年品牌包装资料）",
        "en": "Aspirin 100 mg per tablet; 30 tablets per carton (2024 brand/package material)"
      },
      "imageUrl": null,
      "visualStatus": "source_text_only_no_exact_public_package_image",
      "labeledQuantities": [
        {
          "ingredient": {
            "zh": "阿司匹林",
            "en": "aspirin"
          },
          "value": 100,
          "unit": "mg",
          "basisCode": "per_tablet",
          "basisLabel": {
            "zh": "每片公开资料标示量；不是个人每日片数、加量、换算或换药规则",
            "en": "labelled amount per tablet in the public material; not an individual's daily tablet count, escalation, conversion or switching rule"
          }
        }
      ],
      "concentration": null,
      "container": {
        "typeCode": "carton",
        "typeLabel": {
          "zh": "纸盒",
          "en": "carton"
        },
        "fill": null,
        "countPerPackage": 30,
        "countUnit": {
          "zh": "片/盒",
          "en": "tablets per carton"
        }
      },
      "deliveryDevice": null,
      "compatibleReusableDevice": null,
      "listingStatus": {
        "reviewedAt": "2026-08-30",
        "currentLabelDisplayed": false,
        "ndcDirectoryListed": false,
        "marketAvailability": "not_established",
        "marketingStartDate": null,
        "marketingEndDate": null,
        "purpleBookPresentationStatus": null,
        "statusConflictRequiresManualReview": false
      },
      "package": {
        "count": 30,
        "unit": {
          "zh": "片/盒",
          "en": "tablets per carton"
        }
      },
      "physicalClues": null,
      "comparisonNotice": null,
      "source": {
        "id": "src_9cce1cc5fe0337c1",
        "label": "拜耳中国：拜阿司匹灵® 100 mg、30/90 片新包装公开资料（2024-11-06）",
        "url": "https://www.bayer.com.cn/zh-hans/baiasipilingquanxinbaozhuangshangshi",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "dated_public_record",
        "documentKind": "first_party_release",
        "market": "CN",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-30",
        "reviewedAt": "2026-08-30"
      },
      "scope": "package_and_label_identity_only_not_personal_dosing_or_conversion"
    },
    {
      "id": "cn-bayer-aspirin-enteric-tablet-100mg-90-tablet-dated-pack-record",
      "marketCode": "CN",
      "labelVersion": {
        "zh": "拜耳中国有日期品牌包装资料，2024-11-06；不是现行批准说明书",
        "en": "Dated Bayer China brand/package material, 6 Nov 2024; not a current approved leaflet"
      },
      "dosageForm": {
        "zh": "拜阿司匹灵® 阿司匹林肠溶片",
        "en": "Bayer Aspirin® enteric-coated aspirin tablet"
      },
      "route": {
        "zh": "口服（品牌包装资料中的产品身份字段）",
        "en": "oral (product-identity field in dated brand/package material)"
      },
      "routeCodes": [
        "oral"
      ],
      "productCode": "Bayer China dated pack record: 90 tablets",
      "pouchCode": null,
      "applicationNumber": null,
      "presentationRole": null,
      "primaryStrengthBasisCode": "per_tablet",
      "primaryDisplay": {
        "zh": "每片阿司匹林 100 mg；90 片/盒（2024 年品牌包装资料）",
        "en": "Aspirin 100 mg per tablet; 90 tablets per carton (2024 brand/package material)"
      },
      "imageUrl": null,
      "visualStatus": "source_text_only_no_exact_public_package_image",
      "labeledQuantities": [
        {
          "ingredient": {
            "zh": "阿司匹林",
            "en": "aspirin"
          },
          "value": 100,
          "unit": "mg",
          "basisCode": "per_tablet",
          "basisLabel": {
            "zh": "每片公开资料标示量；不是个人每日片数、疗程、加量、换算或换药规则",
            "en": "labelled amount per tablet in the public material; not an individual's daily tablet count, duration, escalation, conversion or switching rule"
          }
        }
      ],
      "concentration": null,
      "container": {
        "typeCode": "carton",
        "typeLabel": {
          "zh": "纸盒",
          "en": "carton"
        },
        "fill": null,
        "countPerPackage": 90,
        "countUnit": {
          "zh": "片/盒",
          "en": "tablets per carton"
        }
      },
      "deliveryDevice": null,
      "compatibleReusableDevice": null,
      "listingStatus": {
        "reviewedAt": "2026-08-30",
        "currentLabelDisplayed": false,
        "ndcDirectoryListed": false,
        "marketAvailability": "not_established",
        "marketingStartDate": null,
        "marketingEndDate": null,
        "purpleBookPresentationStatus": null,
        "statusConflictRequiresManualReview": false
      },
      "package": {
        "count": 90,
        "unit": {
          "zh": "片/盒",
          "en": "tablets per carton"
        }
      },
      "physicalClues": null,
      "comparisonNotice": null,
      "source": {
        "id": "src_9cce1cc5fe0337c1",
        "label": "拜耳中国：拜阿司匹灵® 100 mg、30/90 片新包装公开资料（2024-11-06）",
        "url": "https://www.bayer.com.cn/zh-hans/baiasipilingquanxinbaozhuangshangshi",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "dated_public_record",
        "documentKind": "first_party_release",
        "market": "CN",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-30",
        "reviewedAt": "2026-08-30"
      },
      "scope": "package_and_label_identity_only_not_personal_dosing_or_conversion"
    }
  ],
  "comparisonPresentations": [],
  "appearanceReferences": [],
  "visualReference": {
    "presentationId": "us-bayer-low-dose-aspirin-enteric-tablet-81mg-200ct-ndc-0280-2100-20",
    "status": "historical_public_label_image_not_product_authentication",
    "imageUrl": "https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=Bayer+Low+Aspirin_200ct_Ctn.jpg&setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&type=img",
    "alt": "BAYER LOW DOSE ASPIRIN 阿司匹林在美国 DailyMed Bayer 公开标签中的 81 mg、200 片装纸盒图",
    "archiveMarket": "美国",
    "labelVersion": "DailyMed 公开标签（Bayer HealthCare，2025-12 更新）",
    "presentation": "BAYER LOW DOSE ASPIRIN：每片阿司匹林 81 mg、肠溶包衣片、200 片装纸盒图（DailyMed Bayer HealthCare 公开标签所列）。",
    "notice": "此为美国 DailyMed Bayer HealthCare 公开标签中对应 BAYER LOW DOSE ASPIRIN、每片阿司匹林 81 mg、肠溶包衣片和 200 片装的纸盒图，只帮助核对品牌、通用名、标示强度、剂型、包装数量和来源；不用于鉴定真伪，也不证明其他包装、其他市场标签、当前可得性、原研身份、目标市场批准、心血管用途或可售资格。",
    "source": {
      "id": "src_3c1cad1341a17717",
      "label": "DailyMed（NLM）：BAYER LOW DOSE ASPIRIN 公开标签（Bayer HealthCare，2025-12 更新）",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&version=8",
      "audience": "public",
      "reviewStatus": "approved",
      "publish": true,
      "documentStatus": "publication_status_unresolved",
      "documentKind": "product_label",
      "market": "US",
      "accessStatus": "public_access_confirmed",
      "accessMode": "public_web_page",
      "accessVerifiedAt": "2026-08-20",
      "reviewedAt": "2026-08-20"
    }
  },
  "visualCoverageNote": null,
  "labelReading": {
    "coverage": "drug_specific_source_review",
    "title": {
      "zh": "阿司匹林说明书放大阅读：先分清美国 81 mg 与中国大陆 100 mg 包装",
      "en": "Aspirin label reading: separate the U.S. 81 mg label from the Mainland-China 100 mg packs first"
    },
    "summary": {
      "zh": "本模块以美国 DailyMed 2025-12 公开标签为警示信息入口，并把拜耳中国 2024 年 100 mg、30/90 片品牌包装资料作为独立的中国大陆身份线索。81 mg 与 100 mg 都是每片标示量，不是网页给出的每日片数；中国品牌新闻也不替代现行批准说明书。",
      "en": "This module uses the December 2025 U.S. DailyMed public label for warning information and keeps Bayer China's dated 2024 material for the 100 mg, 30/90-tablet packs as a separate Mainland-China identity cue. Both 81 mg and 100 mg are labelled amounts per tablet, not web-given daily tablet counts; a China brand announcement is not a substitute for a current approved leaflet."
    },
    "checks": [
      {
        "zh": "先把市场、商品名、阿司匹林、每片标示量、肠溶剂型和实际包装一起核对。美国资料为每片 81 mg；中国大陆有日期品牌资料为每片 100 mg、30 或 90 片。81 mg 和 100 mg 都不是个人每日片数，不能因数字接近而自行换算、补片、隔天轮换或替换。",
        "en": "Check the market, brand, aspirin, labelled amount per tablet, enteric-coated form and actual pack together. The U.S. material is 81 mg per tablet; the dated Mainland-China brand material is 100 mg per tablet in 30- or 90-tablet packs. Neither number is an individual's daily tablet count, and their similarity does not permit self-conversion, extra tablets, alternate-day rotation or substitution."
      },
      {
        "zh": "标签说明这一肠溶包衣产品起效延后，不能据此推导为“更强”“适合所有心脏问题”或可用于需要快速缓解的症状。不要因“阿司匹林”“低剂量”或包装颜色相似而自行添加、隔天轮换、替换抗血小板、抗凝或止痛产品。",
        "en": "The label notes delayed action for this enteric-coated product; that does not mean “stronger,” suitable for every heart concern, or appropriate for symptoms needing rapid relief. Do not self-add, alternate or substitute an antiplatelet, anticoagulant or pain product because of the words “aspirin,” “low dose” or similar package colours."
      },
      {
        "zh": "该标签提示胃出血风险在 60 岁及以上、有胃溃疡或出血问题、合用抗凝药或激素药、合用其他含 NSAID 产品、每日大量饮酒等情形中需要特别核对。请把所有处方药、非处方止痛/感冒药、草本、补充剂和实际药盒一起交给药师或医生；网页不能把这些提示变成个人的“能用/不能用”结论。",
        "en": "The label flags stomach-bleeding questions especially for people age 60 or older, those with ulcer or bleeding history, people using an anticoagulant or steroid, other NSAID-containing products, or substantial daily alcohol. Bring all prescriptions, OTC pain/cold products, herbs, supplements and actual packs to a pharmacist or clinician; a webpage cannot turn these warnings into an individual's “can/cannot use” conclusion."
      },
      {
        "zh": "出现呕血、黑便或血便、晕厥、面部或咽喉肿胀、喘鸣、休克样表现或其他急性严重不适时，应优先使用当地紧急医疗支持；不要等待网页检索或自行用另一种药抵消。",
        "en": "With vomiting blood, black or bloody stools, fainting, facial or throat swelling, wheeze, shock-like symptoms or another acute severe problem, prioritise local emergency medical support; do not wait for a website search or self-counteract with another medicine."
      }
    ],
    "source": {
      "id": "src_3c1cad1341a17717",
      "label": "DailyMed（NLM）：BAYER LOW DOSE ASPIRIN 公开标签（Bayer HealthCare，2025-12 更新）",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&version=8",
      "audience": "public",
      "reviewStatus": "approved",
      "publish": true,
      "documentStatus": "publication_status_unresolved",
      "documentKind": "product_label",
      "market": "US",
      "accessStatus": "public_access_confirmed",
      "accessMode": "public_web_page",
      "accessVerifiedAt": "2026-08-20",
      "reviewedAt": "2026-08-20"
    },
    "scope": "label_literacy_only_no_individual_dosing_or_substitution"
  },
  "mechanismReading": {
    "title": {
      "zh": "阿司匹林怎样起作用：先把 NSAID 标签分类和个人用药决定分开",
      "en": "How aspirin works: keep the NSAID label category separate from individual-use decisions"
    },
    "summary": {
      "zh": "该美国 DailyMed 标签将每片 81 mg 的阿司匹林标示为 NSAID。这个分类可帮助读者识别标签中为何出现胃出血、过敏和与其他 NSAID 同用的警示；它不用于判断一个人是否应使用阿司匹林、适合哪一种产品、能否与抗血小板或抗凝药合用，或怎样调整。",
      "en": "This U.S. DailyMed label identifies its 81 mg aspirin tablet as an NSAID. That category can help a reader understand why the label includes stomach-bleeding, allergy and other-NSAID warnings; it does not determine whether a person should use aspirin, which product is suitable, whether it can be combined with an antiplatelet or anticoagulant, or how to adjust it."
    },
    "checks": [
      {
        "zh": "“NSAID”是标签上的药物类别线索，不是把所有止痛、退热、抗血小板或抗凝产品归为可以互换或联合的依据。不同活性成分、剂型、目标市场标签和个人情况都需要分别核对。",
        "en": "“NSAID” is a label category clue, not a basis to treat all pain, fever, antiplatelet or anticoagulant products as interchangeable or combinable. Active ingredient, dosage form, target-market label and individual context all need separate review."
      },
      {
        "zh": "肠溶包衣描述的是这一准确片剂的制剂特征。它不自动消除出血、过敏或相互作用风险，也不表示可以掰开、研碎、改用不同强度或在有症状时自行加用另一种产品。",
        "en": "Enteric coating describes a formulation feature of this exact tablet. It does not automatically remove bleeding, allergy or interaction risk, or mean that the tablet may be split, crushed, replaced by another strength or supplemented with another product when symptoms occur."
      },
      {
        "zh": "理解标签分类最有用的下一步是让药师或医生用完整药单和现行标签核对风险，而不是根据机制词、包装文字或网络经验自行开始、停用、叠加或替换。",
        "en": "The most useful next step after understanding a label category is to have a pharmacist or clinician check risk using the full medicine list and current label—not to self-start, stop, combine or substitute from a mechanism word, package wording or online experience."
      }
    ],
    "source": {
      "id": "src_3c1cad1341a17717",
      "label": "DailyMed（NLM）：BAYER LOW DOSE ASPIRIN 公开标签（Bayer HealthCare，2025-12 更新；Drug Facts）",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&version=8",
      "audience": "public",
      "reviewStatus": "approved",
      "publish": true,
      "documentStatus": "publication_status_unresolved",
      "documentKind": "product_label",
      "market": "US",
      "accessStatus": "public_access_confirmed",
      "accessMode": "public_web_page",
      "accessVerifiedAt": "2026-08-20",
      "reviewedAt": "2026-08-20"
    },
    "scope": "mechanism_literacy_only_no_individual_dosing_or_substitution"
  },
  "pharmacovigilance": {
    "status": "official_routes_only_no_live_alert_inference",
    "reviewedAt": "2026-08-22",
    "identity": {
      "brand": "BAYER LOW DOSE ASPIRIN",
      "generic": "阿司匹林",
      "dosageFormClass": "肠溶包衣口服片；美国资料每片 81 mg，中国大陆有日期品牌资料每片 100 mg"
    },
    "labelSource": {
      "id": "src_3c1cad1341a17717",
      "label": "DailyMed（NLM）：BAYER LOW DOSE ASPIRIN 公开标签（Bayer HealthCare，2025-12 更新）",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&version=8",
      "audience": "public",
      "reviewStatus": "approved",
      "publish": true,
      "documentStatus": "publication_status_unresolved",
      "documentKind": "product_label",
      "market": "US",
      "accessStatus": "public_access_confirmed",
      "accessMode": "public_web_page",
      "accessVerifiedAt": "2026-08-20",
      "reviewedAt": "2026-08-20"
    },
    "productRoutes": [
      {
        "source": {
          "id": "src_3c1cad1341a17717",
          "label": "DailyMed（NLM）：BAYER LOW DOSE ASPIRIN 公开标签（Bayer HealthCare，2025-12 更新）",
          "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&version=8",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "publication_status_unresolved",
          "documentKind": "product_label",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-20",
          "reviewedAt": "2026-08-20"
        },
        "status": "product_level_public_record_verified",
        "authority": {
          "zh": "美国国家医学图书馆 DailyMed",
          "en": "U.S. National Library of Medicine DailyMed"
        },
        "market": {
          "zh": "美国",
          "en": "United States"
        },
        "recordType": {
          "zh": "公开药品标签",
          "en": "Public medicine label"
        },
        "reviewedAt": "2026-08-20",
        "scope": {
          "zh": "已逐项核对本档案可公开访问的产品级来源入口。该核对不代表已完成所有国家或地区的实时警示检索，也不代表该药存在或不存在当前风险。",
          "en": "This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk."
        }
      }
    ],
    "recordRoute": {
      "status": "product_level_public_record_verified",
      "authority": {
        "zh": "美国国家医学图书馆 DailyMed",
        "en": "U.S. National Library of Medicine DailyMed"
      },
      "market": {
        "zh": "美国",
        "en": "United States"
      },
      "recordType": {
        "zh": "公开药品标签",
        "en": "Public medicine label"
      },
      "reviewedAt": "2026-08-20",
      "scope": {
        "zh": "已逐项核对本档案可公开访问的产品级来源入口。该核对不代表已完成所有国家或地区的实时警示检索，也不代表该药存在或不存在当前风险。",
        "en": "This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk."
      }
    },
    "channels": [
      {
        "id": "china-nmpa-drug-evaluation-centre",
        "authority": "NMPA 药品评价中心",
        "market": {
          "zh": "中国大陆",
          "en": "Mainland China"
        },
        "title": {
          "zh": "药物警戒快讯与安全警示",
          "en": "Drug-vigilance bulletins and safety notices"
        },
        "purpose": {
          "zh": "国家药监局药品评价中心发布的药物警戒快讯、安全警示及药品不良反应监测相关原始入口；具体产品仍须按批准文号、剂型、规格、持有人和公告日期逐项核对。",
          "en": "Primary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item."
        },
        "source": {
          "id": "src_05ff2860226564d4",
          "label": "国家药监局药品评价中心：药物警戒与安全警示入口",
          "url": "https://www.cdr-adr.org.cn/",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "CN",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "fda-drug-safety-communications",
        "authority": "FDA",
        "market": {
          "zh": "美国",
          "en": "United States"
        },
        "title": {
          "zh": "药物安全通讯",
          "en": "Drug Safety Communications"
        },
        "purpose": {
          "zh": "监管机构就重要新安全问题、标签变化或风险沟通发布的原始页面。",
          "en": "Primary FDA pages for important new safety issues, labelling changes and risk communications."
        },
        "source": {
          "id": "src_9177df9e1825aa72",
          "label": "FDA：Drug Safety Communications",
          "url": "https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "fda-medwatch",
        "authority": "FDA MedWatch",
        "market": {
          "zh": "美国",
          "en": "United States"
        },
        "title": {
          "zh": "安全信息与严重问题报告",
          "en": "Safety information and serious-problem reporting"
        },
        "purpose": {
          "zh": "美国 MedWatch 的安全信息和报告入口；报告不等同于已证实因果关系。",
          "en": "U.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality."
        },
        "source": {
          "id": "src_e4739cd55d27ab51",
          "label": "FDA：MedWatch 药品安全信息与不良事件报告计划",
          "url": "https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "adverse_event_reporting",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "ema-pharmacovigilance",
        "authority": "EMA",
        "market": {
          "zh": "欧盟/欧洲经济区",
          "en": "European Union / European Economic Area"
        },
        "title": {
          "zh": "药物警戒概览与 EudraVigilance",
          "en": "Pharmacovigilance overview and EudraVigilance"
        },
        "purpose": {
          "zh": "欧盟药物警戒、疑似不良反应报告和 PRAC 安全评估的官方入口。",
          "en": "Official EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment."
        },
        "source": {
          "id": "src_2ad42a3deae747d1",
          "label": "EMA：Pharmacovigilance overview",
          "url": "https://www.ema.europa.eu/en/human-regulatory-overview/pharmacovigilance-overview",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "EU",
          "accessStatus": "public_access_confirmed",
          "accessMode": "javascript_or_cookie_controls",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "mhra-drug-safety-update",
        "authority": "MHRA",
        "market": {
          "zh": "英国",
          "en": "United Kingdom"
        },
        "title": {
          "zh": "Drug Safety Update",
          "en": "Drug Safety Update"
        },
        "purpose": {
          "zh": "英国 MHRA 面向专业人士和公众的药品安全更新原始发布页。",
          "en": "Primary UK MHRA medicine-safety updates for professionals and the public."
        },
        "source": {
          "id": "src_23fdbe67abeafc63",
          "label": "MHRA：Drug Safety Update",
          "url": "https://www.gov.uk/drug-safety-update",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "UK",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "pmda-drug-safety",
        "authority": "PMDA",
        "market": {
          "zh": "日本",
          "en": "Japan"
        },
        "title": {
          "zh": "药品安全信息",
          "en": "Medicine safety information"
        },
        "purpose": {
          "zh": "日本 PMDA 药品安全信息的英文官方入口；具体产品仍应以日文产品页和现行文件复核。",
          "en": "PMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents."
        },
        "source": {
          "id": "src_06d6be2880f12024",
          "label": "PMDA：Safety Information Regarding Drugs",
          "url": "https://www.pmda.go.jp/english/safety/info-services/drugs/0001.html",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "JP",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "mfds-drug-safety-letters",
        "authority": "MFDS",
        "market": {
          "zh": "韩国",
          "en": "Republic of Korea"
        },
        "title": {
          "zh": "药品安全性书信",
          "en": "Medicine safety letters"
        },
        "purpose": {
          "zh": "韩国 MFDS 发布的药品安全性书信原始索引。原文为韩文，须按涉及产品、剂型、市场和日期逐项阅读；它不自动适用于其他市场，也不构成对个人情况的结论。",
          "en": "MFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case."
        },
        "source": {
          "id": "src_2d7f5018cd05eff4",
          "label": "MFDS：药品安全性书信（韩文原始资料）",
          "url": "https://www.mfds.go.kr/brd/m_545/list.do",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "KR",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "hsa-adverse-events",
        "authority": "HSA",
        "market": {
          "zh": "新加坡",
          "en": "Singapore"
        },
        "title": {
          "zh": "不良反应报告与药物安全信息",
          "en": "Adverse-event reporting and medicine-safety information"
        },
        "purpose": {
          "zh": "新加坡 HSA 面向公众的疑似不良反应报告、药物安全信息与本地监管入口；一份报告不等同于个体因果关系，具体产品仍须按新加坡注册状态、剂型、规格、日期和现行产品资料逐项核对。",
          "en": "HSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information."
        },
        "source": {
          "id": "src_9240397d5a8574c1",
          "label": "HSA：Report adverse events",
          "url": "https://www.hsa.gov.sg/adverse-events/",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "adverse_event_reporting",
          "market": "SG",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "health-canada-medeffect-advisories",
        "authority": "Health Canada",
        "market": {
          "zh": "加拿大",
          "en": "Canada"
        },
        "title": {
          "zh": "MedEffect 加拿大：建议、警告与召回",
          "en": "MedEffect Canada: advisories, warnings and recalls"
        },
        "purpose": {
          "zh": "加拿大政府 Health Canada 的 MedEffect 公开入口，汇集药品及健康产品的建议、警告、召回、报告与安全信息；具体产品仍须按市场、剂型、规格、公告日期和批号逐项核对。",
          "en": "Health Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item."
        },
        "source": {
          "id": "src_212ec921fa6634ad",
          "label": "Health Canada：MedEffect Canada 建议、警告与召回",
          "url": "https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/advisories-warnings-recalls.html",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "CA",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "tga-safety-alerts",
        "authority": "TGA",
        "market": {
          "zh": "澳大利亚",
          "en": "Australia"
        },
        "title": {
          "zh": "药品安全警示",
          "en": "Medicine safety alerts"
        },
        "purpose": {
          "zh": "澳大利亚 TGA 的药品安全警示、建议和监测信息原始发布页。",
          "en": "Primary Australian TGA safety alerts, advisories and monitoring information for therapeutic products."
        },
        "source": {
          "id": "src_ffe6142814f88fac",
          "label": "TGA：Safety alerts",
          "url": "https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "AU",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "swissmedic-pharmacovigilance",
        "authority": "Swissmedic",
        "market": {
          "zh": "瑞士",
          "en": "Switzerland"
        },
        "title": {
          "zh": "药物警戒与不良反应报告",
          "en": "Pharmacovigilance and suspected adverse-reaction reporting"
        },
        "purpose": {
          "zh": "瑞士 Swissmedic 的药物警戒、信号评估和疑似不良反应官方入口；报告或信号本身不等同于对个体因果关系的确认。",
          "en": "Official Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality."
        },
        "source": {
          "id": "src_c854f813ce2671df",
          "label": "Swissmedic：Pharmacovigilance",
          "url": "https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/pharmacovigilance.html",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "adverse_event_reporting",
          "market": "CH",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "medsafe-safety-communications",
        "authority": "Medsafe",
        "market": {
          "zh": "新西兰",
          "en": "New Zealand"
        },
        "title": {
          "zh": "药品安全通讯",
          "en": "Medicine safety communications"
        },
        "purpose": {
          "zh": "新西兰 Medsafe 面向公众和专业人士的药品安全通讯与归档入口；旧公告可能已被现行产品资料更新。",
          "en": "New Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information."
        },
        "source": {
          "id": "src_3510c1a523ec9769",
          "label": "Medsafe：Safety Communications",
          "url": "https://www.medsafe.govt.nz/safety/SafetyCommunications.asp",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "NZ",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "sahpra-safety-information",
        "authority": "SAHPRA",
        "market": {
          "zh": "南非",
          "en": "South Africa"
        },
        "title": {
          "zh": "药物安全信息、警示与药物警戒",
          "en": "Medicine safety information, alerts and pharmacovigilance"
        },
        "purpose": {
          "zh": "南非 SAHPRA 面向公众和专业人士的药物安全信息、警示与药物警戒入口；官方警示不等同于产品在所有情形下不安全，具体产品仍须按南非注册状态、剂型、规格、公告日期与现行资料逐项核对。",
          "en": "SAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information."
        },
        "source": {
          "id": "src_25b0aaefee742163",
          "label": "SAHPRA：Safety Information Updates / Pharmacovigilance",
          "url": "https://www.sahpra.org.za/safety-information-and-updates/",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "ZA",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "who-medicine-safety-alerts",
        "authority": "WHO",
        "market": {
          "zh": "全球",
          "en": "Global"
        },
        "title": {
          "zh": "药品与疫苗安全警示档案",
          "en": "Medicine and vaccine safety-alert archive"
        },
        "purpose": {
          "zh": "WHO 的跨市场安全警示档案；每条历史警示必须按公告日期、涉及产品和市场单独阅读。",
          "en": "WHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market."
        },
        "source": {
          "id": "src_9a7dc56ec34c7e1a",
          "label": "WHO：Safety alerts for medicines and vaccines",
          "url": "https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/safety-alerts",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "GLOBAL",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      },
      {
        "id": "anvisa-pharmacovigilance",
        "authority": "Anvisa",
        "market": {
          "zh": "巴西",
          "en": "Brazil"
        },
        "title": {
          "zh": "药物警戒、警示与 VigiMed",
          "en": "Pharmacovigilance, alerts and VigiMed"
        },
        "purpose": {
          "zh": "巴西 Anvisa 的药物警戒原始入口，涵盖警示、药物警戒公告、风险沟通和 VigiMed 报告路径；具体产品仍须按巴西批准状态、剂型、规格和公告日期逐项核对。",
          "en": "Anvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item."
        },
        "source": {
          "id": "src_5de362c12580111d",
          "label": "Anvisa：Farmacovigilância（药物警戒、警示与 VigiMed）",
          "url": "https://www.gov.br/anvisa/pt-br/assuntos/fiscalizacao-e-monitoramento/farmacovigilancia",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "official_safety_monitoring",
          "documentKind": "regulatory_safety_communication",
          "market": "BR",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-22",
          "reviewedAt": "2026-08-22"
        }
      }
    ],
    "notices": [],
    "boundary": {
      "zh": "本卡将逐药产品级来源与 15 个市场级官方警戒入口放在同一处核验；它不表示已完成该药在所有国家或地区的实时警示检索，也不表示该药存在新的安全警示、召回或风险结论。请先以品牌名、通用名、剂型、规格、所在市场和公告日期逐项匹配；不要仅因看到标题自行停药、换药、加量或减量。",
      "en": "This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline."
    },
    "scope": "official_routes_only_no_live_alert_inference"
  },
  "archive": {
    "summary": "美国 DailyMed 2025-12 BAYER LOW DOSE 标签列为每片阿司匹林 81 mg 的肠溶包衣口服片；拜耳中国 2024 年有日期公开资料把拜阿司匹灵®列为每片 100 mg 的阿司匹林肠溶片，并列出 30 片与 90 片包装。此页帮助把市场、商品名、每片毫克数、剂型和实际包装一起阅读；不把 81 mg 或 100 mg 换算成个人片数，也不判断任何人是否需要阿司匹林、怎样联用或是否应停用。",
    "history": "本页把美国当前 OTC 标签与中国大陆有日期品牌包装资料分开保存。中国大陆公开资料可证明 2024 年发布时的 100 mg、30/90 片包装线索，但不是现行批准说明书，不能据此推定当前批准文号、完整用法、供应或可售状态。‘低剂量’‘肠溶/安全包衣’和相似包装均不能跨市场推导可替代性或个人方案；多种影响出血的药物同时使用时，应由药师或医生核对完整药单。",
    "sourceDocuments": [
      {
        "id": "src_3c1cad1341a17717",
        "label": "DailyMed（NLM）：BAYER LOW DOSE ASPIRIN 公开标签（Bayer HealthCare，2025-12 更新）",
        "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&version=8",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "publication_status_unresolved",
        "documentKind": "product_label",
        "market": "US",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-20",
        "reviewedAt": "2026-08-20"
      },
      {
        "id": "src_9cce1cc5fe0337c1",
        "label": "拜耳中国：拜阿司匹灵® 100 mg、30/90 片新包装公开资料（2024-11-06）",
        "url": "https://www.bayer.com.cn/zh-hans/baiasipilingquanxinbaozhuangshangshi",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "dated_public_record",
        "documentKind": "first_party_release",
        "market": "CN",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-30",
        "reviewedAt": "2026-08-30"
      },
      {
        "id": "src_f6ae0e06d563a6a2",
        "label": "FDA：药物相互作用消费者信息",
        "url": "https://www.fda.gov/drugs/resources-drugs/drug-interactions-what-you-should-know",
        "audience": "public",
        "reviewStatus": "approved",
        "publish": true,
        "documentStatus": "publication_status_unresolved",
        "documentKind": "public_health_reference",
        "market": "US",
        "accessStatus": "public_access_confirmed",
        "accessMode": "public_web_page",
        "accessVerifiedAt": "2026-08-20",
        "reviewedAt": "2026-08-20"
      }
    ],
    "applicationNumber": "DailyMed U.S. OTC label record",
    "approvalTimeline": [
      {
        "date": "2025-12",
        "title": {
          "zh": "DailyMed 公开标签版本",
          "en": "DailyMed public label version"
        },
        "detail": {
          "zh": "本页链接 2025-12 的 DailyMed 美国 OTC 公开标签作为可复核阅读入口。它标识该具体公开标签，不推定初始批准年份、NDA 编号、当前供应、持有人或其他市场状态。",
          "en": "This page links the 2025-12 DailyMed U.S. OTC public label as a traceable reading entry point. It identifies that specific public label and does not assert an original-approval year, NDA number, current availability, holder or another-market status."
        },
        "source": {
          "id": "src_3c1cad1341a17717",
          "label": "DailyMed: BAYER LOW DOSE aspirin public OTC label",
          "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&version=8",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "publication_status_unresolved",
          "documentKind": "product_label",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-20",
          "reviewedAt": "2026-08-20"
        }
      }
    ],
    "marketStatus": [
      {
        "market": {
          "zh": "美国",
          "en": "United States"
        },
        "status": {
          "zh": "已链接 OTC 公开标签",
          "en": "OTC public label linked"
        },
        "detail": {
          "zh": "仅对应本页所列 DailyMed OTC 文件。",
          "en": "Only the DailyMed OTC document listed on this page is linked."
        }
      },
      {
        "market": {
          "zh": "中国大陆、欧盟、日本",
          "en": "Mainland China, EU, Japan"
        },
        "status": {
          "zh": "待逐项建立市场记录",
          "en": "Market record not established"
        },
        "detail": {
          "zh": "不从美国 OTC 标签推定当地批准、持有人、规格、供应或可售资格。",
          "en": "No local approval, holder, strength, supply or sale-eligibility conclusion is inferred from the U.S. OTC label."
        }
      }
    ],
    "frequentlyAskedQuestions": [
      {
        "question": {
          "zh": "美国 OTC 标签能代表其他市场或个人用法吗？",
          "en": "Does a U.S. OTC label represent another market or personal use?"
        },
        "answer": {
          "zh": "不能。它仅是这一具体美国公开标签的阅读入口；目标市场的现行文件和个人情况必须分别由专业人员核对。",
          "en": "No. It is only a reading entry point for this specific U.S. public label; the current target-market document and individual circumstances need separate professional review."
        }
      },
      {
        "question": {
          "zh": "为什么不把 OTC 档案写成原始批准或原研结论？",
          "en": "Why does the OTC archive not state original approval or originator conclusions?"
        },
        "answer": {
          "zh": "标签记录不足以证明这些结论。它们需要可追溯的产品、剂型、市场、时间和一手监管记录，并经人工审核。",
          "en": "A label record is insufficient to prove those conclusions. They require traceable product, dosage-form, market, date and primary regulatory records with human review."
        }
      }
    ],
    "relatedMedicineChecks": [
      {
        "target": {
          "id": "coumadin",
          "brand": "Coumadin",
          "generic": "华法林钠",
          "canonicalUrls": {
            "zh": "https://origindrug.com/drugs/coumadin/",
            "en": "https://origindrug.com/en/drugs/coumadin/"
          }
        },
        "title": {
          "zh": "与 COUMADIN／华法林同在药单上时：阿司匹林 81 mg 也应先核对",
          "en": "When COUMADIN / warfarin is on the same list: aspirin 81 mg also needs review first"
        },
        "summary": {
          "zh": "BAYER LOW DOSE ASPIRIN 的当前美国公开 Drug Facts 将正在使用抗凝药列为胃出血警示中需要先核对的线索。本卡片只提示把实际阿司匹林包装、华法林包装、其他止痛/感冒药、处方药、非处方药、草本和补充剂交给药师或医生核对；它不判断任何人能否同服，也不建议自行停用、错开时间、替换或调整任何一种药。开始使用或其他变动同样需要先由药师或医生核对。",
          "en": "The current U.S. public Drug Facts for BAYER LOW DOSE ASPIRIN lists use of an anticoagulant as a cue that needs review in its stomach-bleeding warning. This card only signals that the actual aspirin pack, warfarin pack, other pain/cold products, prescriptions, OTC products, herbs and supplements need review by a pharmacist or clinician; it does not decide whether anyone can use them together or advise self-stopping, time-separation, replacement or adjustment of either medicine. Starting a medicine or making another change also needs pharmacist or clinician review."
        },
        "source": {
          "id": "src_3c1cad1341a17717",
          "label": "DailyMed（NLM）：BAYER LOW DOSE ASPIRIN 当前美国公开标签（Bayer HealthCare；SPL v8，抗凝药警示）",
          "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=075b103e-0bb4-4b7a-ac0e-5645bcbd0a07&version=8",
          "audience": "public",
          "reviewStatus": "approved",
          "publish": true,
          "documentStatus": "publication_status_unresolved",
          "documentKind": "product_label",
          "market": "US",
          "accessStatus": "public_access_confirmed",
          "accessMode": "public_web_page",
          "accessVerifiedAt": "2026-08-20",
          "reviewedAt": "2026-08-20"
        },
        "scope": "review_complete_medicine_list_no_self_directed_change"
      }
    ],
    "relatedArticleSlugs": [
      "medicine-label-for-everyday-questions",
      "how-to-read-a-drug-label",
      "regulatory-sources-first"
    ]
  },
  "canonicalUrls": {
    "zh": "https://origindrug.com/drugs/bayer-low-dose-aspirin/",
    "en": "https://origindrug.com/en/drugs/bayer-low-dose-aspirin/"
  },
  "limitations": [
    "No originator, generic, interchangeability, availability, price, holder, strength or sale-eligibility conclusion is inferred beyond the linked source documents.",
    "Target-market current labels and official records must be checked separately."
  ]
}